Since they won't blame Leo if their IPIX investment fails
It's not that they won't blame Leo. It's that they won't blame themselves.
They didn't research the market forces running amok in the antibiotic market that rendered B-ABSSSI nonviable. It really seems like Leo didn't either.
Combine that with a Prurisol failure, muddy B-OM data, a dogshite B-UP deal, and stopping Kevetrin phase 2 at two patients (really? We couldn't make it to 10?)...what do people expect .
Since then (2020 and beyond) we had a successful 6-person phase 1 B-UC tablet test for safety and some great pre-clinical COVID results (as we did with Prurisol).
Let's hope B-COVID can turn this trend around.
CTIX/IPIX was cleared of Rosen/Mako in June 2016 at a stock price of $1.80. From there on it's on Leo.
Market Data 
Markets 
AI
